Fisher Asset Management LLC Has $1.07 Million Position in Integra LifeSciences Holdings Co. (NASDAQ:IART)

Fisher Asset Management LLC lowered its holdings in Integra LifeSciences Holdings Co. (NASDAQ:IART - Free Report) by 88.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 47,198 shares of the life sciences company's stock after selling 352,525 shares during the quarter. Fisher Asset Management LLC owned about 0.06% of Integra LifeSciences worth $1,070,000 as of its most recent filing with the SEC.

Several other large investors have also made changes to their positions in the company. KBC Group NV increased its holdings in Integra LifeSciences by 65.2% in the third quarter. KBC Group NV now owns 2,839 shares of the life sciences company's stock valued at $52,000 after purchasing an additional 1,120 shares during the last quarter. New York State Teachers Retirement System increased its holdings in shares of Integra LifeSciences by 3.0% in the third quarter. New York State Teachers Retirement System now owns 90,098 shares of the life sciences company's stock worth $1,637,000 after acquiring an additional 2,616 shares in the last quarter. Nisa Investment Advisors LLC grew its holdings in shares of Integra LifeSciences by 599.6% during the fourth quarter. Nisa Investment Advisors LLC now owns 3,267 shares of the life sciences company's stock worth $74,000 after buying an additional 2,800 shares in the last quarter. Nordea Investment Management AB grew its holdings in shares of Integra LifeSciences by 4.1% during the fourth quarter. Nordea Investment Management AB now owns 127,908 shares of the life sciences company's stock worth $2,919,000 after buying an additional 5,032 shares in the last quarter. Finally, Choreo LLC boosted its position in Integra LifeSciences by 29.9% during the fourth quarter. Choreo LLC now owns 22,274 shares of the life sciences company's stock valued at $500,000 after purchasing an additional 5,123 shares during the last quarter. Institutional investors and hedge funds own 84.78% of the company's stock.

Remove Ads

Analysts Set New Price Targets

Separately, Morgan Stanley began coverage on Integra LifeSciences in a research report on Monday, December 2nd. They set an "underweight" rating and a $20.00 price target for the company. Three research analysts have rated the stock with a sell rating, five have issued a hold rating and one has issued a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus target price of $23.00.

Integra LifeSciences Stock Performance

Shares of IART traded up $0.97 during mid-day trading on Friday, reaching $23.00. The company's stock had a trading volume of 602,570 shares, compared to its average volume of 655,883. Integra LifeSciences Holdings Co. has a 1-year low of $16.81 and a 1-year high of $36.80. The stock has a market cap of $1.78 billion, a P/E ratio of -255.53, a PEG ratio of 0.73 and a beta of 1.23. The business has a 50-day simple moving average of $23.79 and a two-hundred day simple moving average of $21.90. The company has a current ratio of 1.20, a quick ratio of 0.73 and a debt-to-equity ratio of 0.79.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last released its quarterly earnings data on Tuesday, February 25th. The life sciences company reported $0.97 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.85 by $0.12. Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. The company had revenue of $442.65 million during the quarter, compared to analysts' expectations of $445.15 million. During the same period last year, the firm posted $0.89 earnings per share. The business's revenue was up 11.5% on a year-over-year basis. As a group, equities research analysts anticipate that Integra LifeSciences Holdings Co. will post 2.45 earnings per share for the current fiscal year.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.